Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2010

Ansén Sascha, Bangard Christopher, Querings Silvia, Gabler Franziska, Scheffler Matthias, Seidel Daniela, Saal Beate, Zander Thomas, Nogová Lucia, Töpelt Karin, Markert Eva, Stoelben Erich, Ernestus Karen, Thomas Roman K, Wolf Jürgen

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Bone Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Osteoblasts

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 20186030
DOI: 10.1097/JTO.0b013e3181cf32aa

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.PMID 20186030Read ↗

Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.Semantic proximity Read ↗

Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.Semantic proximity Read ↗

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.Semantic proximity Read ↗

Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.Semantic proximity Read ↗

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.Semantic proximity Read ↗

Osteoblast-Like Cells in Human Cancers: New Cell Type and Reliable Markers for Bone MetastasisSemantic proximity Read ↗

Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.Semantic proximity Read ↗

Osteosclerotic Change as a Therapeutic Response to Gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone MetastasisSemantic proximity Read ↗

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.Semantic proximity Read ↗

Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone MetastasesSemantic proximity Read ↗

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

The effect of bevacizumab for bone scintigraphy imaging: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.